ViatrisHAM:VIA +1.71%58 EBITDA Margin % is 15.61% as of Mar. 2026, which is 32% below its 10-year median of 23.10. GuruFocus rates HAM:VIA with a GF Score™ of 58/100 and a GF Value™ of €9.77 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 955 Drug Manufacturers companies, Viatris ranks better than 61.57% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Viatris's EBITDA for the
three
months ended in Mar. 2026 was €475 Mil. Viatris's Revenue for the
three
months ended in Mar. 2026 was €3,042 Mil. Therefore, Viatris's EBITDA margin for the quarter that ended in Mar. 2026 was 15.61%.
Viatris (HAM:VIA) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Viatris EBITDA Margin % Related Terms
Viatris EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Viatris's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:VIA vs NBIX, UTHR, ELAN: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Viatris's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris (HAM:VIA) has a EBITDA Margin % of 15.61% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Viatris and its competitors. This is 32% below median its historical median of 23.10. According to the industry distribution chart, Viatris ranks #367 out of 955 companies in the Drug Manufacturers industry, placing it in the top 38.4%.
Is Viatris' EBITDA Margin % too high?
Viatris' current EBITDA Margin % of 15.61% is 32% below median its 10-year median of 23.10. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Viatris' value of 15.61% is 25.5% above this industry median. Based on the distribution chart, Viatris ranks #367 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Viatris has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' EBITDA Margin % compare to NBIX and UTHR?
According to the Drug Manufacturers industry distribution chart, Viatris ranks #367 out of 955 companies for EBITDA Margin %. This puts Viatris in the upper half of its industry. The industry median EBITDA Margin % is 12.44. Viatris' value of 15.61% is 25.5% above this benchmark. While the company's 10-year median is 23.10 vs. the industry median of 12.44, Viatris has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viatris's current EBITDA Margin % of 15.61% is 25.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Viatris and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viatris's current EBITDA Margin % is 15.61%, which is 32% below median its own 10-year median of 23.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (HAM:VIA) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.77, compared to a current price of €14.26 — trading 45.9% above its estimated fair value. The current EBITDA Margin % is 15.61%, which is 32% below median its 10-year median of 23.10 and 25.5% above the Drug Manufacturers industry median of 12.44. Viatris' overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Viatris (HAM:VIA), the current EBITDA Margin % is 15.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viatris (HAM:VIA) Overvalued in 2026?
Based on GuruFocus' analysis, Viatris stock appears to be overvalued.
The current stock price of €14.26 is trading 45.9% above its estimated GF Value™ of €9.77.
GuruFocus considers Viatris to be Significantly Overvalued.
Key valuation signals for HAM:VIA:
EBITDA Margin %: 15.61% (32% below median its 10-year median of 23.10)
GF Value™: €9.77 vs. price of €14.26 (45.9% above fair value)
Industry Position: 25.5% above the Drug Manufacturers median (#367 of 955)
No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
58GF Score
Get the complete analysis for HAM:VIA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:VIA has been successfully added to your 
